Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Martin

Pain Medicine Henderson, NV Medical Doctor

NPI 1386622462 CMS profile 107675

2705 W Horizon Ridge Pkwy, Ste 120, Henderson, NV 89052

Open in the dashboard

General payments

$5,845

145 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Martin of Henderson, NV is reported in the CMS Open Payments database as having received $5,845 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46 2
2024 General $384 12
2023 General $680 17
2022 General $342 11
2021 General $1,072 24
2020 General $1,814 37
2019 General $1,507 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Martin
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Scott Martin were reported at $46. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Scott Martin Pain Medicine median Middle half National median
2019 $1,507 $409 $115–$1,311 $163
2020 $1,814 $214 $66–$666 $114
2021 $1,072 $299 $84–$899 $132
2022 $342 $335 $103–$1,149 $149
2023 $680 $376 $114–$1,228 $160
2024 $384 $387 $115–$1,173 $164
2025 $46 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,631 119 payments
  2. Stryker Corporation $232 3 payments
  3. Revance Therapeutics, Inc. $177 3 payments
  4. Nevro Corp. $169 3 payments
  5. Goode Surgical Inc $160 1 payment
  6. Novo Nordisk Inc $125 1 payment
  7. Merz North America, Inc. $98 1 payment
  8. Shire North American Group Inc $76 4 payments
  9. Dexcom, Inc. $54 3 payments
  10. Arbor Pharmaceuticals, Inc. $23 1 payment
  11. Other $100 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,845 145 payments
Products named General payments · program years 2019–2025
  1. Octrode SCS Leads Cardiac Arrhythmias and Heart Failure $1,460 33 payments
  2. Octrode SCS Leads Neuromodulation $603 16 payments
  3. Penta SCS Leads Cardiac Arrhythmias and Heart Failure $495 7 payments
  4. OCTRODE $403 16 payments
  5. Penta SCS Leads Neuromodulation $205 3 payments
  6. PENTA $205 4 payments
  7. Prodigy Family of SCS IPGs $189 4 payments
  8. DAXXIFY $177 3 payments
  9. Senza Spinal Cord Stimulation System $169 3 payments
  10. PROCLAIM $165 5 payments
  11. Other $1,650 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$3,668

Medicare's payments for the services billed

Medicare patients

20

Average age 74

Services billed

59

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Depression 65%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $177
$177 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record